An Early Phase 1 interventional study of 89Zr-Trastuzumab Human Dosimetry and Safety and HER2 Positive Lesion Detection and Safety in Breast Cancer, sponsored by Washington University School of Medicine. Completed at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-10-13.
Sponsored by Washington University School of Medicine · Early Phase 1, Interventional, and Diagnostic
How we know · 2 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 80 studies in Breast Neoplasms by Washington University School of Medicine — 18 open to participants now, 22 under way, none of them phase 3. Breast Neoplasms · Washington University School of Medicine.
Among the 80 studies in Breast Neoplasms by Washington University School of Medicine, this one is the 39th largest by enrollment of the 74 interventional ones that give a count, is one of 6 that started in 2014, is one of 17 in phase 1, and was the 32nd registered.
14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →18 of the 80 studies in Breast Neoplasms by Washington University School of Medicine are open now, in 1 country. Recruiting first, the newest first:
Washington University School of Medicine · Sites in United States
Ages 18+ · Women only
Washington University School of Medicine · Sites in United States
Ages 25–55 · Women only · Healthy volunteers
Washington University School of Medicine · Sites in United States
Ages 18+ · Women only
Washington University School of Medicine · Sites in United States
Ages 18+
Washington University School of Medicine · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
80 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 19 · Phase 2 31
First in 2002; this study’s year is marked. 6 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 52 is below the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 55 across the 74 interventional studies, 100 across the 6 observational. Of the 53 that completed or were terminated, 22 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
Washington University School of Medicine is the lead sponsor of 1,806 studies on the registry; 271 are open to participants now.
Of its 329 completed or terminated interventional studies of FDA-regulated products, 216 (66%) have results posted.
5 of the studies in Breast Neoplasms by Washington University School of Medicine that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04354064Washington University School of MedicineCirculating Tumor DNA (ctDNA) for Early Treatment Response Assessment of Solid Tumors | 2026-12-31 |
| NCT02476786Washington University School of MedicineEndocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score | 2027-01-31 |
| NCT00353483Washington University School of MedicineEffect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells | 2027-08-31 |
| NCT06864754Washington University School of MedicineWashU DIEP Flap Video and Patient Understanding Improvement | 2027-10-31 |
| NCT05837455Washington University School of MedicineNeoTAILOR: ABiomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-positive, HER2-negative Breast Cancer | 2027-11-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 80 studies in Breast Neoplasms by Washington University School of Medicine, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to see if Positron Emission Tomography (PET-Imaging) with 89Zr labeled trastuzumab can detect trastuzumab (HER2) positive breast cancer.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
89Zr-Trastuzumab Human Dosimetry and Safety
Drug: 89Zr-Trastuzumab Human Dosimetry and Safety · Drug: HER2 Positive Lesion Detection and Safety
HER2 Positive Lesion Detection and Safety
Drug: 89Zr-Trastuzumab Human Dosimetry and Safety · Drug: HER2 Positive Lesion Detection and Safety
PET Imaging following administration of 89Zr labeled Trastuzumab for calculation of human dosimetry and overall safety
Detection of HER2 Positive Breast Cancer with 89Zr Labeled Trastuzumab and PET imaging
This study also gives TrastuzumabStudies of TrastuzumabTrastuzumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.
Number of Participants With Adverse Events as a Measure of Safety and Tolerability After 89Zr-Trastuzumab Administration
Subjects medical record was followed for 30 days following 89Zr-Trastuzumab Administration for AE Assessment with AE being defined as Any unfavorable medical occurrence in a human subject who receives 89Zr-Trastuzumab and PET/CT imaging, including any abnormal sign, symptom, or disease. The event does not necessarily have to be causally related to injection of 89Zr-Trastuzumab or PET/CT imaging to qualify as an adverse event, just temporally related.
Time frame: 30 Days following 89Zr-Trastuzumab Administration
Study first enrollment occurred in February 2014 and closed to enrollment 31 December 2017. Subjects were recruited from those patients being seen by medical oncology at Siteman Cancer Center. Planned enrollment was 67 participants with a total of 52 subjects enrolled with evaluable data at the end of the grant period.
| Milestone | Cohort 1 | Cohort 2: Lesion Detection and Safety |
|---|---|---|
| Started | 12 | 40 |
| Completed | 12 | 40 |
| Not completed | 0 | 0 |
Subjects medical record was followed for 30 days following 89Zr-Trastuzumab Administration for AE Assessment with AE being defined as Any unfavorable medical occurrence in a human subject who receives 89Zr-Trastuzumab and PET/CT imaging, including any abnormal sign, symptom, or disease. The event does not necessarily have to be causally related to injection of 89Zr-Trastuzumab or PET/CT imaging to qualify as an adverse event, just temporally related.
| participants | Cohort 1 | Cohort 2: Lesion Detection and Safety |
|---|---|---|
| Number of Participants With Adverse Events as a Measure of Safety and Tolerability After 89Zr-Trastuzumab Administration | 1 | 1 |
Collected over Subjects were monitored for adverse events for the 30 days following 89Zr-Trastuzumab administration. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1 | 0/12 (0%) | 0/12 (0%) | 1/12 (8.3%) |
| Cohort 2: Lesion Detection and Safety | 0/40 (0%) | 0/40 (0%) | 1/40 (2.5%) |
| Event | Cohort 1 | Cohort 2: Lesion Detection and Safety |
|---|---|---|
| non-neutropenic feverGeneral disorders | 1/12 | 0/40 |
| Flu Like SymptomsGeneral disorders | 1/12 | 0/40 |
| Acute Kidney InjuryRenal and urinary disorders | 0/12 | 1/40 |
| SepsisInfections and infestations | 0/12 | 1/40 |
| Age, Customized(years) | Cohort 1 | Cohort 2: Lesion Detection and Safety | Total |
|---|---|---|---|
| Mean | 56.9 (29 to 74) | 56 (37 to 78) | 56.5 (29 to 78) |
| Sex: Female, Male(Participants) | Cohort 1 | Cohort 2: Lesion Detection and Safety | Total |
|---|---|---|---|
| Female | 12 | 40 | 52 |
| Male | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1 | Cohort 2: Lesion Detection and Safety | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 1 |
| Not Hispanic or Latino | 12 | 39 | 51 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(participants) | Cohort 1 | Cohort 2: Lesion Detection and Safety | Total |
|---|---|---|---|
| United States | 12 | 40 | 52 |
PDFs hosted by the registry, ClinicalTrials.gov.
The record gives a start of Feb 2014, a primary completion of Dec 2017 and a completion of Feb 2018. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2022, 4 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Washington University School of Medicine →